Navigation Links
GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc.
Date:11/26/2007

oups. There was no clinically significant change in visual acuity in the patients who had new opacities reported nor was any patient, including those with opacities noted at baseline, discontinued from therapy because of a decrease in visual acuity.

A three-year, double-blind, placebo-controlled study in hypercholesterolemic patients to assess the effect of lovastatin on the human lens demonstrated that there were no clinically or statistically significant differences between the lovastatin and placebo groups in the incidence, type or progression of lenticular opacities. There are no controlled clinical data assessing the lens available for treatment beyond three years.

Clinical Studies in Adolescent Patients

Efficacy of Lovastatin in Adolescent Boys with Heterozygous Familial Hypercholesterolemia

In a double-blind, placebo-controlled study, 132 boys 10-17 years of age (mean age 12.7 yrs) with heterozygous familial hypercholesterolemia (heFH) were randomized to lovastatin (n=67) or placebo (n=65) for 48 weeks. Inclusion in the study required a baseline LDL-C level between 189 and 500 mg/dL and at least one parent with an LDL-C level >189 mg/dL. The mean baseline LDL-C value was 253.1 mg/dL (range: 171-379 mg/dL) in the MEVACOR group compared to 248.2 mg/dL (range: 158.5-413.5 mg/dL) in the placebo group. The dosage of lovastatin (once daily in the evening) was 10 mg for the first 8 weeks, 20 mg for the second 8 weeks, and 40 mg thereafter.

MEVACOR significantly decreased plasma levels of total-C, LDL-C and apolipoprotein B (see Table IV).

TABLE IV Lipid-lowering Effects of Lovastatin in Adolescent Boys with Heterozygous

Familial Hypercholesterolemia

(Mean Percent Change from Baseline at week 48 in Intention-to-Treat

Population)

DOSAGE N TOTAL-C LDL-C HDL-C TG.* Apolipoprotein B

P
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine news :

1. GlaxoSmithKline Responds to JAMA Articles
2. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
3. Congressional Black Caucus Foundation and GlaxoSmithKline Announce Supplier Business Initiative Study Results
4. AUDIO from Medialink and GlaxoSmithKline: A New Nasal Spray for Allergy Relief
5. Mylan Announces Settlement of Paroxetine Hydrochloride Extended-Release Tablets with GlaxoSmithKline
6. GlaxoSmithKline Aids California Fire Relief Efforts
7. Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program
8. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
9. Southwest Ambulance Awarded Exclusive, 3-Year Contract Extension in Peoria, Arizona
10. Crdentias VP of Marketing, Christina Hogan, Provides Exclusive Interview on Marketing Strategy
11. Pearson VUE Signs Exclusive Contract with Educational Resources, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... (PRWEB) May 26, 2015 General ... with MarkLogic Corporation. The alliance ensures joint customers ... platform and General Networks’ expertise in building enterprise ... and MarkLogic will help customers integrate, manage and ... and business processes. , “Our customers are seeking ...
(Date:5/26/2015)... 2015 Javon Bea President and ... for using her quality improvement and organizational development expertise ... also provides leadership and direction for the financial, budget, ... Home Health Care and Mercy Durable Medical Equipment. , ... administration with the last 20 in home care administration. ...
(Date:5/26/2015)... 2015 Beginning this fall, Boston University ... online Master of Social Work (MSW) program . Already ... Charles River Campus, the online option will be offered ... Standing option is open to applicants holding an undergraduate ... Work Education. Students entering the program will be granted ...
(Date:5/25/2015)... The report “Liver Failure – ... the therapeutic development for Liver Failure. The report ... MOAs to produce first-in-class and best-in-class products. Complete ... Failure with 22 market data tables and 14 ... http://www.rnrmarketresearch.com/liver-failure-pipeline-review-h1-2015-market-report.html . , Companies discussed in ...
(Date:5/25/2015)... May 26, 2015 The National ... as a 2015-2016 inductee into its VIP Professional Woman ... prestigious distinction for leadership in dentistry. NAPW is the ... more than 700,000 members and over 200 operating local ... this exceptional group of professional women,” said NAPW President ...
Breaking Medicine News(10 mins):Health News:General Networks Corporation Announces Alliance with MarkLogic 2Health News:Boston University to Offer Online Master of Social Work Advanced Standing Option 2Health News:Boston University to Offer Online Master of Social Work Advanced Standing Option 3Health News:Liver Failure Pipeline Assessment and Key Players Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Liver Failure Pipeline Assessment and Key Players Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Liver Failure Pipeline Assessment and Key Players Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:National Association of Professional Women Inducts Dr. Laquinas Hooked, D.D.S. of General Dentist, Into its VIP Professional Woman of the Year Circle 2
... smokers say they,are likely to quit smoking because it is ... researchers. , The study, published Tuesday ... researchers looked at the smoking behaviors,of people who own or ... lived with a dog, cat or bird. , ...
... panel of pain-management experts representing the American Pain Society ... Pain Medicine (AAPM) has published the first comprehensive clinical ... pain medications for patients with chronic non-cancer pain. ... The Journal of Pain , www.jpain.org , ...
... PARI Respiratory Equipment launched two updated continuing ... with seven classes for respiratory therapists, nurses, case ... as group programs that are pre-approved for continuing ... Certification (CCMC), American Association of Respiratory Care (AARC), ...
... of Bio-IT World magazine, today announced the launch of a ... enterprise --www.ecliniqua.com. , ... Needham, MA ... publisher of Bio-IT World magazine, today announced the launch of ...
... use a new, cutting edge diagnostic technology to ... outcomes.WOBURN, Mass. and VEDBAEK, Denmark, Feb. 10 AdvanDx ... Rockford, Illinois has implemented AdvanDx,s PNA FISH(R) tests ... earlier than conventional methods to help their physicians, ...
... WESTFORD, Mass., Feb. 10 Cynosure, Inc. (Nasdaq: ... a broad array of light-based aesthetic treatment systems, today ... ended December 31, 2008. Fourth-Quarter 2008 Financial Results ... the three months ended December 31, 2008 were $25.5 ...
Cached Medicine News:Health News:Smokers Likely to Quit for Fido's Health, Not Their Own 2Health News:New guidelines for prescribing opioid pain drugs published 2Health News:New guidelines for prescribing opioid pain drugs published 3Health News:New guidelines for prescribing opioid pain drugs published 4Health News:PARI Respiratory Equipment Launches 2 New Continuing Ed Classes 2Health News:Cambridge Healthtech Media Group Launches Clinical Trials Web Site 2Health News:Cambridge Healthtech Media Group Launches Clinical Trials Web Site 3Health News:OSF Saint Anthony Medical Center Implements PNA FISH(R) Tests to Help Provide Best Care for Patients with Bloodstream Infections 2Health News:OSF Saint Anthony Medical Center Implements PNA FISH(R) Tests to Help Provide Best Care for Patients with Bloodstream Infections 3Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 2Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 3Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 4Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 5Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 6Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 7Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 8Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 9Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 10Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 11Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 12Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 13
(Date:5/22/2015)... THOUSAND OAKS, Calif. , May 22, ... today announced the Company has commenced termination ... commercialization of brodalumab with AstraZeneca (LON:AZN, STO:AZN ... investigational IL-17 inhibitor, is in development for ... and axial spondyloarthritis.  The decision was based ...
(Date:5/22/2015)... , May 22, 2015  BioLife Solutions, Inc. (NASDAQ: ... clinical grade hypothermic storage and cryopreservation freeze ... cells and tissues ("BioLife" or the "Company"), announced that the ... Conference. The Company is scheduled to present ... 27, 2015 at the Grand Hyatt Hotel in ...
(Date:5/22/2015)... , May 22, 2015 The North ... 2014 and is estimated to reach $90.7 million by 2019, ... Browse through the TOC of North America Dental Lasers ... the help of various tables and figures. ... customization on this report.   Dental lasers ...
Breaking Medicine Technology:Amgen to terminate participation in co-development and commercialization of brodalumab 2Amgen to terminate participation in co-development and commercialization of brodalumab 3Amgen to terminate participation in co-development and commercialization of brodalumab 4Amgen to terminate participation in co-development and commercialization of brodalumab 5BioLife Solutions To Present At The 2015 Marcum MicroCap Conference In New York City 2North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 2North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: